Golden has been acquired by ComplyAdvantage.Read about it here ⟶

LoQus23

LoQus23 is a small molecule drugs developer for Huntington's disease founded in 2019 by David Reynolds.

Overview Structured Data Issues Contributors Activity

loqus23.com

Is a

Company

Organization

Company attributes

Industry

Health technology

Biotechnology

Location

United Kingdom

Cambridge, Cambridgeshire

CEO

Founder

Pitchbook URL

pitchbook.com/profiles...277398-91

Number of Employees (Ranges)

1 – 10

Full Address

Building 522 Babraham Research Campus Cambridge CB22 3AT, UK0

Investors

Dementia Discovery Fund

Novartis Venture Fund

Forbion Capital Partners

Founded Date

2019

Total Funding Amount (USD)

52,300,000

Latest Funding Round Date

October 2, 2024

Latest Funding Type

Series A

Country

United Kingdom

Other attributes

Company Operating Status

Active

Latest Funding Round Amount (USD)

43,000,000

No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more companies like LoQus23

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.

Open Query Tool

Access by API